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As of June 21, coronavirus SARS-CoV-2 has infected almost 9
milions of people and the number of laboratory-confirmed COrona-
VIrus Disease 2019 (COVID-19) deaths are 461,715, worldwide [1].
The virus causes acute respiratory distress syndrome (SARS) and,
eventually, death from multiple organ failure, in a non-neglectable
portion of patients [2]. As such, COVID-19 is an international public
health emergency. Although some recent reports suggested the efficacy
of diverse agents, there is currently no standard therapy for COVID-19.
Several preclinical studies showed that doxycycline (DOX) and
minocycline (MIN), semi-synthetic tetracyclines frequently used in
clinical practice against a variety of infective agents and well tolerated,
are also effective against some RNA viruses [3,4]. It is commonly re-
cognized that tetracyclines act selectively inhibiting microbial protein
synthesis by binding to the 16S rRNA [5]. Recent evidence suggested
that the precise site of interaction between DOX/MIN and 16S rRNA as
well as other cellular RNA molecules could be double-stranded RNAs
(dsRNAs) [6]. The dsRNA-binding mechanism could explain the tetra-
cyclines broad antimicrobial and antiviral properties [6]. Indeed,
rRNAs form numerous double-stranded structures that are essential to
protein synthesis. Furthermore, dsRNAs have been observed as inter-
mediates of the viral replication of positive-stranded viruses, including
SARS coronaviruses [7,8]. SARS-CoV-2 is a positive-stranded RNA virus
and, interestingly, DOX/MIN antiviral efficacy was hitherto reported
mostly against positive-sense RNA viruses [3,4]. Besides, replication of
RNA viruses occurs in the host cell cytoplasm, where Mg + concentra-
tion is most favorable to DOX/MIN binding [5]. As such, DOX/MIN may
be effective also against SARS-CoV-2 infection. In this regard, accu-
mulating evidence shows that SARS is associated with an aberrant in-
duction of inflammatory cytokines/chemokines, mostly activated by
dsRNA intermediates of viral replication [9,10]. In particular, the ro-
bust viral replication and delayed IFN-γ signaling accompanying the
initial steps of SARS seem to be consequence of the coronavirus ability
to initially evade the host dsRNA-sensors [10,11]. Therefore, it is
plausible that early administration of dsRNA-binding DOX/MIN may
reduce the risk of SARS. This hypothesis is strengthened by the fact that
both DOX and MIN are known to have relevant anti-inflammatory
properties [12]. In detail, the tetracyclines inhibit pro-inflammatory
cytokines and matrix metalloproteinases that play a key role in cor-
onavirus acute infection and are involved in chemokine activation and
in tissue destruction, such as perivascular basement membrane and
parenchymal extracellular matrix, thereby facilitating inflammatory
cells infiltration [12,13]. Of note, also this immunomodulatory effect
seems to be dsRNA-mediated [5]. Hence, DOX/MIN may inhibit both
the viral replication and the host exuberant inflammatory response.
Taken together, all evidence suggests that DOX/MIN may be active
against SARS-CoV-2 and clinical trials investigating these drugs are
urgently warranted.
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